06.29.15
REACH Separations plans to double lab space at its headquarters in Nottingham UK and is investing in analytical equipment and purification systems. Growth for purification is being driven by increased demand for chromatography capabilities from the drug discovery, contract research and agrochemical sectors across Europe.
Phil Abbott, technical group director said, “This venture is a major milestone for our organization and essentially enables us to do more of what we’ve already been doing over the last few years, but at even greater speed for even more customers. Our clients typically require purified materials as quickly as possible. Our expanded resource and capacity will allow us to work at increased speed to help reduce screen time and get compounds back to clients even quicker, helping meet tight deadlines.”
The company’s growth has also been bolstered by a strategic alliance with Evotec that provides ongoing purification, analytical and small molecule chromatography in support of Evotec’s pharma and biopharma clients.
Reach supports clients in the fields of chiral, reverse phase and normal phase chromatography from mg scale to in excess of 500g.
Phil Abbott, technical group director said, “This venture is a major milestone for our organization and essentially enables us to do more of what we’ve already been doing over the last few years, but at even greater speed for even more customers. Our clients typically require purified materials as quickly as possible. Our expanded resource and capacity will allow us to work at increased speed to help reduce screen time and get compounds back to clients even quicker, helping meet tight deadlines.”
The company’s growth has also been bolstered by a strategic alliance with Evotec that provides ongoing purification, analytical and small molecule chromatography in support of Evotec’s pharma and biopharma clients.
Reach supports clients in the fields of chiral, reverse phase and normal phase chromatography from mg scale to in excess of 500g.